Tff Pharmaceuticals Inc (TFFP) - News Archive

TFF Pharmaceuticals Announces Wind Down of Operations FORT WORTH, Texas, November 14, 2024 TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) has made a significant announcement regarding the future of the company. In a recent st...

The quest for improved delivery methods for pharmaceutical treatments has led researchers to explore diverse routes, with inhalational therapy gaining momentum due to its potential for localized and efficient drug admin...

In an unprecedented cooperative effort aimed at innovating treatments for respiratory illnesses, TFF Pharmaceuticals has formed a strategic partnership with Emory University and the Biomedical Advanced Research and Deve...

In a significant development for public health, TFF Pharmaceuticals recently announced promising preclinical data from its bivalent universal influenza vaccine candidates. Manufactured by TFF, these vaccine candidates d...

This article reports on the ongoing favorable outcomes from TFF Pharmaceuticals Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) designed for the prevention of lung transplant rejection, noting accelerated patien...

: This article discusses the recent engagement of Outcome Capital as a strategic advisor by TFF Pharmaceuticals, a clinical-stage biopharmaceutical company. The article highlights the company s focus on developing innov...

Accelerating Innovations: Regulatory and Preclinical Advances in TFF Pharmaceuticals Pipeline Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical ProgramIn a significant stride towards pioneering advanc...

The field of biodefense has significantly evolved in recent years with the emergence of novel threats, necessitating the development of more efficient and rapid countermeasures. In line with this , TFF Pharmaceuticals a...

Influenza viruses pose a global health challenge each year, with seasonal strains causing significant illness and mortality rates, and pandemic outbreaks leading to widespread devastation. Existing annual flu vaccines,...

TFF Pharmaceuticals Increases Investment Potential with Successful Public OfferingFORT WORTH, Texas - TFF Pharmaceuticals, Inc (Nasdaq: TFFP), a clinical-stage biopharmaceutical company specializing in innovative drug p...

In the continually advancing field of biopharmaceuticals, TFF Pharmaceuticals has shone as a beacon of innovation. The biopharmaceutical company s latest contribution to the field of medical research, specifically, in t...

TFF Pharmaceuticals, a groundbreaking player in the field of pharmaceuticals, recently disclosed additional optimistic data acquired from their ongoing Phase 2 trial of Tacrolimus Inhalation Powder, visually abbreviated...

TFF Pharmaceuticals, a cutting-edge pharmaceutical company focused on developing innovative inhalable drug therapies, recently updated their clinical programs for Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole...

TFF Pharmaceuticals Secures $1.2 Million in Funding through Registered Direct Offering: A Milestone for Innovation in BiopharmaceuticalsIn a significant move towards advancing its innovative drug products, TFF Pharmaceu...

Fort Worth-based biopharmaceutical company, TFF Pharmaceuticals, has recently announced a registered direct offering priced at-the-market under Nasdaq rules. The company has entered into definitive agreements for the pu...

In the world of pharmaceutical sciences, continuous research and clinical development efforts are paramount. TFF Pharmaceuticals, a renowned pharmaceutical company, has recently announced an important update on their cl...

TFF Pharmaceuticals: Unveiling Promising Phase 2 Trial Results for TFF VORI and TFF TAC TFF Pharmaceuticals, a cutting-edge pharmaceutical company at the forefront of novel drug delivery solutions, is scheduled to host...